Another ASCO and more CAR-T data. Arcellx presented early results on its multiple myeloma therapy at last weekend’s ASCO annual meeting, and we dig into what it would take to stand up to J&J's Carvykti. But that’s not all. People were on their feet for the Enhertu breast cancer drug and its unheard-of results. We’ve got a lot to share about ASCO. Also under discussion is Fierce's special report on the rising stars in the medtech and healthcare fields and what they have in common. Lastly, we finally have boots-on-the-ground at an industry conference. Our reporter headed out to the first in-person ASCO since the pandemic started. She planned to learn about new data releases and discoveries, and also found out something surprising about herself. 

<<podcast embed>>

To learn more about the topics in this episode: 
Fierce Healthcare and Fierce Medtech's 17 rising stars in health tech
ASCO: AstraZeneca, Daiichi’s Enhertu could transform breast cancer treatment with landmark HER2-low show
ASCO: Gilead's Trodelvy limps forward in new breast cancer lane as below-par showing casts doubt
ASCO: ‘Any way you slice’ it, Arcellx's CAR-T is matching J&J-Legend’s Carvykti, analyst says
ASCO: Medidata links CAR-T's cytokine release syndrome risk to common biomarkers in new study
ASCO: Black breast cancer patients want to participate in trials, but adequate information is hard to come by
Emergent says J&J owes up to $420M for breach of contract. J&J: You want to talk breaches?
ADA: Eli Lilly's stellar tirzepatide weight loss data tee up showdown with Novo Nordisk's Wegovy, analysts say
ADA: With promising long-term data for its artificial pancreas, Medtronic aims to fully close the diabetes management loop
UPDATE: Bristol Myers strikes up Roche rivalry with $4.1B Turning Point buy
Eli Lilly wins key dispute over patient warnings in era of DTC advertising
ASCO: Return to in-person 'zoo that it always was,' with added COVID challenges—and bad shoes

The Top Line is produced by senior multimedia producer Teresa Carey with editor-in-chief Tracy Staton, managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists.

Another ASCO and more CAR-T data. Arcellx&nbsp;presented&nbsp;early results on its multiple myeloma&nbsp;therapy at last weekend&rsquo;s ASCO annual meeting, and we dig into what it would take to stand up to J&amp;J's Carvykti. But that&rsquo;s not all. People were on their feet for the Enhertu breast cancer drug and its unheard-of results. We&rsquo;ve got a lot to share about ASCO.&nbsp;Also under discussion is Fierce's special report on the rising stars in the medtech and healthcare fields and what they have in common. Lastly, we finally have boots-on-the-ground at an industry conference. Our reporter headed out to the first in-person ASCO since the pandemic started. She planned to learn about new data releases and discoveries, and also found out something surprising about herself.&nbsp;
&lt;&lt;podcast embed&gt;&gt;
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercehealthcare.com/health-tech/rising-stars-health-tech" data-cke-saved-href="https://www.fiercehealthcare.com/health-tech/rising-stars-health-tech">Fierce Healthcare and Fierce Medtech's 17 rising stars in health tech</a></li>
<li><a href="https://www.fiercepharma.com/pharma/asco-astrazeneca-daiichis-enhertu-transform-breast-cancer-treatment-practice-changing-her2" data-cke-saved-href="https://www.fiercepharma.com/pharma/asco-astrazeneca-daiichis-enhertu-transform-breast-cancer-treatment-practice-changing-her2">ASCO: AstraZeneca, Daiichi&rsquo;s Enhertu could transform breast cancer treatment with landmark HER2-low show</a></li>
<li><a href="https://www.fiercepharma.com/pharma/asco-gileads-trodelvy-limps-forward-new-breast-cancer-lane-below-par-showing-casts-doubt" data-cke-saved-href="https://www.fiercepharma.com/pharma/asco-gileads-trodelvy-limps-forward-new-breast-cancer-lane-below-par-showing-casts-doubt">ASCO: Gilead's Trodelvy limps forward in new breast cancer lane as below-par showing casts doubt</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/asco-any-way-you-slice-it-arcellxs-car-t-matching-jj-legends-carvykti-analyst-says" data-cke-saved-href="https://www.fiercebiotech.com/biotech/asco-any-way-you-slice-it-arcellxs-car-t-matching-jj-legends-carvykti-analyst-says">ASCO: &lsquo;Any way you slice&rsquo; it, Arcellx's CAR-T is matching J&amp;J-Legend&rsquo;s Carvykti, analyst says</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/asco-medidata-links-car-ts-cytokine-release-syndrome-risk-common-biomarkers-new-study" data-cke-saved-href="https://www.fiercebiotech.com/biotech/asco-medidata-links-car-ts-cytokine-release-syndrome-risk-common-biomarkers-new-study">ASCO: Medidata links CAR-T's cytokine release syndrome risk to common biomarkers in new study</a></li>
<li><a href="https://www.fiercebiotech.com/cro/black-breast-cancer-patients-want-participate-trials-adequate-information-hard-come-survey" data-cke-saved-href="https://www.fiercebiotech.com/cro/black-breast-cancer-patients-want-participate-trials-adequate-information-hard-come-survey">ASCO: Black breast cancer patients want to participate in trials, but adequate information is hard to come by</a></li>
<li><a href="https://www.fiercepharma.com/pharma/emergent-says-jj-owes-420m-breach-contract-jj-fires-back-you-want-talk-breaches" data-cke-saved-href="https://www.fiercepharma.com/pharma/emergent-says-jj-owes-420m-breach-contract-jj-fires-back-you-want-talk-breaches">Emergent says J&amp;J owes up to $420M for breach of contract. J&amp;J: You want to talk breaches?</a></li>
<li><a href="https://www.fiercepharma.com/pharma/ada-2022-eli-lillys-stellar-tirzepatide-weight-loss-data-tee-showdown-novo-nordisks-wegovy" data-cke-saved-href="https://www.fiercepharma.com/pharma/ada-2022-eli-lillys-stellar-tirzepatide-weight-loss-data-tee-showdown-novo-nordisks-wegovy">ADA: Eli Lilly's stellar tirzepatide weight loss data tee up showdown with Novo Nordisk's Wegovy, analysts say</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/ada-medtronic-plots-fully-close-diabetes-management-loop" data-cke-saved-href="https://www.fiercebiotech.com/medtech/ada-medtronic-plots-fully-close-diabetes-management-loop">ADA: With promising long-term data for its artificial pancreas, Medtronic aims to fully close the diabetes management loop</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/bms-strikes-roche-rivalry-41b-acquisition-turning-point" data-cke-saved-href="https://www.fiercebiotech.com/biotech/bms-strikes-roche-rivalry-41b-acquisition-turning-point">UPDATE: Bristol Myers strikes up Roche rivalry with $4.1B Turning Point buy</a></li>
<li><a href="https://www.fiercepharma.com/marketing/washington-supreme-court-sides-eli-lilly-dispute-over-patient-warnings-era-dtc" data-cke-saved-href="https://www.fiercepharma.com/marketing/washington-supreme-court-sides-eli-lilly-dispute-over-patient-warnings-era-dtc">Eli Lilly wins key dispute over patient warnings in era of DTC advertising</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/asco-back-person-first-time-years-not-without-its-challenges" data-cke-saved-href="https://www.fiercebiotech.com/biotech/asco-back-person-first-time-years-not-without-its-challenges">ASCO: Return to in-person 'zoo that it always was,' with added COVID challenges&mdash;and bad shoes</a></li>
</ul>
The Top Line is produced by senior multimedia producer Teresa Carey with editor-in-chief Tracy Staton, managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our &ldquo;Fierce&rdquo; journalists.&nbsp;

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement